In an article written by Antonanzas, Rive, Badenas, Gomez- Lus and Guilhaume (2006), the different style of treatment of Alzheimer’s Disease (AD) was found to have implications on research. In the United States and many other developed countries, AD patients are often institutionalized at a certain point of the disease when they are said to cause a burden on their caregivers. In Spain, AD is rarely a disease that institutionalizes a person; they are regularly taken care of by a caregiver in the community till the end. Researchers in Spain found that due to their different views on AD care, much of the research available could not be applied to their country and adaptions to research had to be made. Researchers had their sights set on finding out whether drugs that lowered care costs in countries that institutionalized AD patients would have the same effect in a country that mainly does not (p. 137).
The purpose of the research done by Antonanzas and colleagues was to determine the cost benefits and the benefits on health and quality of life (if any) of using the Federal Drug Administration (FDA) approved drug Memantine. After seeing improvements in the cost reduction of care in the US and other developed countries, researchers in Spain adapted a model to fit their style of care for AD patients. They hoped to find out whether Memantine would help improve the lives of AD patients, their caregivers, and the country itself (Antonanzas, Rive, Badenas, Gomez-Lus, & Guilhaume, 2006, p. 137).
Researchers involved in the study on Memantine, sought to answer whether the already lower costs of AD care in Spain could be lowered even more by the use of the only drug approved for use in moderate to severe AD. The lower costs of care in Spain were found to be due to the infrequent institutionalization (nursing homes or long term hospital stays) of AD patients compared to other countries, though the use of in-home care does not come with out some burdens of cost and caregiver isolation. Research also sought to determine whether Memantine would increase the length of independence of an AD patient, as it had in many other countries (Antonanzas et al., 2006, p.137). The information found in this article was supported by many different peer-reviewed sources. Some of the sources were those that determined Memantine’s helpfulness in countries such as the United States and Finland, but many also found supported the Spanish researchers’ findings. In the article, forty-three references are sited as being used (Antonanzas et al., 2006, p.144).
For the study, researchers randomly chose 252 participants. The clinical trial had one specific criterion to allow for Memantine to be properly used as the FDA suggests, subjects had to be diagnosed with moderately severe to severe AD, therefore the population was diagnosed AD patients (Antonanzas et al., 2006, p.139). The design used for this study was a “double-blind placebo controlled clinical trial”...